Cargando…
1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves
BACKGROUND: The effects of age and interval between vaccine doses on COVID-19 are incompletely understood, yet critical for public health policy. METHODS: This analysis evaluated the effectiveness of an mRNA-1273 50 μg booster (3(rd) dose) in ∼17,000 boosted participants in the phase 3 coronavirus e...
Autores principales: | Follmann, Dean, Wang, Xiaowei, Gilbert, Peter, Baden, Lindsey R, El Sahly, Hana M, Essink, Brandon, Marovich, Mary, Janes, Holly, Deng, Weiping, Priddy, Frances, Dixit, Avika, Tomassini, Joanne, Das, Rituparna, Miller, Jacqueline, Zhou, Honghong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678540/ http://dx.doi.org/10.1093/ofid/ofad500.2470 |
Ejemplares similares
-
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022) -
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
por: Pajon, Rolando, et al.
Publicado: (2022) -
Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021) -
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
por: Benkeser, David, et al.
Publicado: (2023) -
Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study
por: Kim, Yoo-Yeon, et al.
Publicado: (2023)